



For more information:
Consuelo Trillo Díaz
ctrillo@rovi.es
Tel: + 34 91 244 44 10

AWARDED A PARTIALLY REFUNDABLE GRANT FOR THE DEFINITION OF THE DESIGN SPACE BY THE APPLICATION OF THE QBD METHODOLOGY FOR ISM® FORMULATIONS

Madrid – 31th of March 2018

ROVI is a company committed with innovation, with more than 399 granted patents and 106 applications in progress. Currently, ROVI's R&D projects are focused in two investigation platforms: Glycomics and ISM®, being this last one an extended drugs system, owned by ROVI, intended to improve patient's treatment compliance.

ROVI received in 2017 the support of the Centro para el Desarrollo Tecnológico Industrial (CDTI) on its Research and Developments activities, with the provision of a partially repayable grant co-funded by the the European Union's European Regional Development Fund (FEDER) through the intelligent growth multi-regional program. This program is included in the frame of employment growth investment objective, in its Priority Axis 01 01 (Promote investigation, technological development and innovation) and Specific Objective 1.1.2 (R&D Institutions building reinforcement, consolidation and improvement of technological and scientific infrastructures).

These funds will be used to finance R&D&I activities in the frame of the "Definición del espacio de diseño mediante la aplicación de la metodología QbD para formulaciones ISM®" project, with dossier number IDI-20170024.



About ROVI

ROVI is a fully integrated Spanish specialist pharmaceutical company dedicated to research, development, manufacture under license and marketing of small molecules and biological specialties. The Company has a diversified portfolio of products which it has been marketing in Spain through a specialist sales team, devoted to visiting medical specialists, hospitals and pharmacies. ROVI's portfolio, with 30 main products marketed, is currently focused on its flagship product, Bemiparin, a second-generation low-weight heparin developed internally. ROVI's product portfolio in the research and development phase is mainly focused on meeting medical needs that are currently unsatisfied; developing new products based on low-molecular-weight heparins (LMWH) and expanding the indications for existing products also based on LMWH. ROVI manufactures the active ingredient Bemiparin for its main patented products and for the injectable pharmaceutical products developed by its own team of researchers and uses its filling and packaging capacity to offer a wide range of third-party manufacturing services for some of the leading international pharmaceutical companies, mainly in the area of preloaded syringes. For further information, visit www.rovi.es.